Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/pbc.29295 http://scihub22266oqcxt.onion/10.1002/pbc.29295 34398511!8441639!34398511     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34398511&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Pediatr+Blood+Cancer 2021 ; 68 (11): e29295 Nephropedia Template TP {{tp|p=34398511|t=2021. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase |pdf=|usr=}}{{34398511}} gab.com Text Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase JO: Pediatr Blood Cancer http://www.kidney.de/pget.php?&tw=1&pmid=34398511 #FOAvip Vaccinationis a critical tool in the prevention of COVID-19 infection for individuals and for communities. The mRNA vaccines contain polyethylene glycol (PEG) as a stabilizer. Currently, in North America, only the BNT162b2 (Pfizer-BioNTech) mRNA vaccine is approved for individuals aged 12-17. Most patients treated with contemporary regimens for acute lymphoblastic leukemia receive PEG-asparaginase (PEG-ASNase) and 10%-30% will develop allergic reactions. Optimizing access and safety for vaccine administration for these patients is critical. This report describes a process developed to support COVID vaccination in a cohort of adolescents and young adults with a history of PEG-ASNase allergy. Twit Text FOAVip Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase ????Pediatr Blood Cancer http://www.kidney.de/pget.php?&tw=1&pmid=34398511 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34398511 #FOAvip English Wikipedia <ref>{{Cite pmid|34398511}}</ref> Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase #MMPMID34398511 Mark C; Gupta S; Punnett A; Upton J; Orkin J; Atkinson A; Clarke L; Heisey A; McGovern C; Alexander S Pediatr Blood Cancer 2021[Nov]; 68 (11): e29295 PMID34398511show ga Vaccinationis a critical tool in the prevention of COVID-19 infection for individuals and for communities. The mRNA vaccines contain polyethylene glycol (PEG) as a stabilizer. Currently, in North America, only the BNT162b2 (Pfizer-BioNTech) mRNA vaccine is approved for individuals aged 12-17. Most patients treated with contemporary regimens for acute lymphoblastic leukemia receive PEG-asparaginase (PEG-ASNase) and 10%-30% will develop allergic reactions. Optimizing access and safety for vaccine administration for these patients is critical. This report describes a process developed to support COVID vaccination in a cohort of adolescents and young adults with a history of PEG-ASNase allergy. |Adolescent[MESH] |Adult[MESH] |Antineoplastic Agents/*adverse effects[MESH] |Asparaginase/*adverse effects[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/administration & dosage/adverse effects/*therapeutic use[MESH] |COVID-19/complications/*prevention & control[MESH] |Child[MESH] |Drug Hypersensitivity/*complications/etiology[MESH] |Humans[MESH] |Polyethylene Glycols/*adverse effects[MESH] |Precursor Cell Lymphoblastic Leukemia-Lymphoma/*complications/drug therapy[MESH]Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 v(epmc).pdf DeepDyve Pubget Overpricing